(Ninth China International Import Expo) Senior executives of foreign companies: The China International Import Expo will allow global innovation achievements to meet China’s needs faster

China News Service, Shanghai, November 5 (Reporter Chen Jing) The 9th China International Import Expo (referred to as the "CIIE") opened in Shanghai on the 5th. In the medical equipment and pharmaceutical and health care exhibition area, multinational companies placed their latest approved or world-first products in the most conspicuous positions, and the booths were crowded with people.

"The CIIE will allow global innovation achievements to meet China's needs faster." Eli Lilly Group Vice President and General Manager of China Dehlan said in an interview, "We will continue to accelerate the introduction of global innovation and work with all parties to transform more scientific breakthroughs into health values ​​accessible to patients." Eli Lilly's booth ran a "150 Years of Scientific Exploration" timeline throughout the entire venue, focusing on displaying a series of its cutting-edge innovations in the four core disease fields of cardiometabolic diseases, neuroscience, tumors and immunity.

Merck’s booth showcases about 30 innovative drugs that have been approved in China, covering the fields of oncology, vaccines, cardiovascular metabolism, anti-infections and rare diseases. Two new products - Xinruilai® (soltecept for injection) and Anfuchang® (clerovimab injection) made their debut at the CIIE. The former is the world's first breakthrough biological agent targeting the core pathological mechanism of pulmonary arterial hypertension. It was commercially launched in China in June this year, bringing the treatment of pulmonary arterial hypertension from "treating the symptoms" to "treating the root cause". The latter is used to prevent lower respiratory tract infections caused by respiratory syncytial virus (RSV) in newborns and infants. Tang Kaiyu, global senior vice president of Merck and president of Merck China, said: "In the next five years, Merck expects to have more than 50 new products and new indications approved in China."

At the Boston Scientific booth, more than 100 innovative products were dazzling. The main booth brings together the world's cutting-edge technologies in the field of minimally invasive medicine and China's local innovations, focusing on breakthrough technologies such as comprehensive management of atrial fibrillation and precise coronary intervention under image guidance. Since its first exhibition in 2019, 26 CIIE exhibits have been approved for sale in China. One of the most eye-catching products this year is the world’s first domestically produced C-Sheath electrode lead guide sheath set. This product is derived from the needs and insights accumulated by Chinese doctors during operations, and then promotes product design and technological improvements. It is an example of local innovation going global. (over)